Eli Lilly and Co (LLY) Position Increased by Palladium Partners LLC

Palladium Partners LLC lifted its stake in Eli Lilly and Co (NYSE:LLY) by 42.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 207,303 shares of the company’s stock after purchasing an additional 61,350 shares during the period. Eli Lilly and makes up 1.4% of Palladium Partners LLC’s investment portfolio, making the stock its 21st largest holding. Palladium Partners LLC’s holdings in Eli Lilly and were worth $17,732,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Hartland & Co. LLC raised its position in Eli Lilly and by 4.4% during the first quarter. Hartland & Co. LLC now owns 10,386 shares of the company’s stock worth $874,000 after acquiring an additional 438 shares during the last quarter. Rothschild Asset Management Inc. raised its position in Eli Lilly and by 4.1% during the first quarter. Rothschild Asset Management Inc. now owns 883,359 shares of the company’s stock worth $74,299,000 after acquiring an additional 35,136 shares during the last quarter. Simmons Bank raised its position in Eli Lilly and by 1.1% during the first quarter. Simmons Bank now owns 38,103 shares of the company’s stock worth $3,205,000 after acquiring an additional 418 shares during the last quarter. Northwest Quadrant Wealth Management LLC raised its position in Eli Lilly and by 0.5% during the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after acquiring an additional 19 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its position in Eli Lilly and by 798.7% during the first quarter. Teacher Retirement System of Texas now owns 854,735 shares of the company’s stock worth $71,892,000 after acquiring an additional 759,625 shares during the last quarter. Hedge funds and other institutional investors own 76.30% of the company’s stock.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The disclosure for this sale can be found here. In the last three months, insiders sold 651,088 shares of company stock valued at $56,439,586. Company insiders own 0.20% of the company’s stock.

LLY has been the subject of a number of research reports. BMO Capital Markets restated a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a research report on Thursday, September 28th. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research report on Friday, October 13th. Jefferies Group restated a “buy” rating and set a $89.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, Goldman Sachs Group restated a “buy” rating and set a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $90.25.

Eli Lilly and Co (NYSE LLY) opened at $85.61 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market cap of $95,475.95, a P/E ratio of 21.20, a PEG ratio of 1.79 and a beta of 0.35. Eli Lilly and Co has a 52-week low of $72.68 and a 52-week high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.82% and a return on equity of 15.37%. The company’s revenue was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.88 earnings per share. analysts forecast that Eli Lilly and Co will post 4.22 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is currently 98.58%.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/22/eli-lilly-and-co-lly-position-increased-by-palladium-partners-llc.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit